Merck (NYSE: MRK) announced results from its Phase 3 CORALreef Lipids trial showing that enlicitide decanoate, an investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE